Lu Zong-liang, Du Bao-min, Chen Zuo, Wu Yang-feng, Yu Xue-hai, Zhao Yu-chen
Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
Zhonghua Xin Xue Guan Bing Za Zhi. 2005 Dec;33(12):1067-70.
To elucidate whether lipid-lowering therapy with Xuezhikang can induce a decrease of cardiac events and an attenuation of total mortality in coronary heart disease (CHD) patients with diabetes.
We designed a random, double-blinded, placebo controlled clinical trial in selected 591 patients. All patients were administrated with capsule Xuezhikang (0.6 g, Bid) or placebo in addition to conventional therapy. The mean follow-up period was four years. The primary end-points were nonfatal myocardial infarction and death from CHD.
(1) The incidence of CHD events and that of death from CHD were reduced by 50.8% (P = 0.0008) and by 44.1% (P = 0.0246) in treatment group, respectively; Also, the incidence of nonfatal myocardial infarction was reduced by 63.8% (P = 0.0151). (2) The incidence of stroke, tumor, and PCI/CABG were decreased by 20.2%. (3) The total mortality were lowered by 44.1% in treatment group (P = 0.0097).
Xuezhikang can effectively reduce the incidence of cardiac events and total mortality in CHD patients with diabetes.
阐明血脂康降脂治疗能否降低糖尿病冠心病（CHD）患者的心脏事件发生率及总死亡率。
我们设计了一项随机、双盲、安慰剂对照的临床试验，选取591例患者。所有患者在接受常规治疗的基础上，服用血脂康胶囊（0.6 g，每日2次）或安慰剂。平均随访期为4年。主要终点为非致死性心肌梗死和CHD死亡。
（1）治疗组CHD事件发生率和CHD死亡率分别降低了50.8%（P = 0.0008）和44.1%（P = 0.0246）；此外，非致死性心肌梗死发生率降低了63.8%（P = 0.0151）。（2）中风、肿瘤及PCI/CABG的发生率降低了20.2%。（3）治疗组总死亡率降低了44.1%（P = 0.0097）。
血脂康可有效降低糖尿病CHD患者的心脏事件发生率和总死亡率。
